TABLE 3.
Candida species | Period |
Antifungal drug MIC50/MIC90 (µg/ml) (range) % resistant (R) isolatesa |
||||||
---|---|---|---|---|---|---|---|---|
Fluconazole | Voriconazole | Posaconazole | Amphotericin B | Caspofungin | Anidulafungin | Micafungin | ||
Candida albicans |
Period 1 |
0.25 / 0.50 (0.06‐1) R : 0% |
0.01 / 0.02 (0.01‐0.06) R : 0% |
0.5 / 0.5 (0.13‐1) ND |
0.032 / 0.13 (<0.03‐0.25) R : 0% |
|||
Period 2 |
0.25 / 0.50 (<0.06‐2) R : 0% |
/ 0.03 (<0.008‐0.12) R : 0% |
0.015 / 0.042 (0.015‐0.50) ND |
0.5 / 1 (0.05‐1) ND |
0.03 / 0.06 (<0.03‐1) R :2% |
0.03 / 0.06 (<0.03‐0.25) R : 0% |
0.01 / 0.03 (<0.01 ‐ 0.5) R : 0% |
|
Candida glabrata |
Period 1 |
16 / 64 (4‐128) R : 12% |
0.25 / 0.5 (0.06‐2) ND |
0.5 / 1 (0.13‐1) ND |
0.06 / 0.13 (0.02‐0.25) R :0% |
|||
Period 2 |
8 / 16 (1‐32) R :0% |
0.25 / 0.5 (0.06‐4) ND |
0.5 / 2 (0.05‐2) ND |
1 / 1 (0.06‐1) ND |
0.06 / 0.13 (0.03‐0.25) R : 0% |
0.03 / 0.06 (<0.03‐1) R : 6% |
0.015 / 0.015 (<0.01‐0.12) R : 0% |
|
Candida tropicalis |
Period 1 |
1 / 2 (0.5‐4) R : 0% |
0.03 / 0.25 (0.01‐0.25) R : 0% |
0.25 / 0.5 (0.13‐0.5) ND |
0.03 / 0.5 (0.03‐0.5) R : 0% |
|||
Period 2 |
2 / 2 (0.25‐2) R : 0% |
0.12 / 0.25 (0.01‐0.25) R : 0% |
0.12 / 0.5 (0.02‐0.5) ND |
0.5 / 1 (0.5‐1) ND |
0.03 / 0.12 (0.02‐0.12) R : 0% |
0.03 / 0.12 (0.02 ‐ 0.12) R : 0% |
0.02 / 0.06 (0.02‐0.12) R : 0% |
|
Candida parapsilosis |
Period 1 |
2 / 2 (2‐2) R : 0% |
0.03 / 0.03 (0.03) R : 0% |
0.25 / 0.5 (0.25 / 0.5) ND |
0.25 / 0.5 (0.25‐0.5) R : 0% |
|||
Period 2 |
0.5 / 0.5 (0.5) R : 0% |
0.008 / 0.01 (0.008‐0.02) R : 0% |
0.015 / 0.026 (<0.015 ‐ 0.026) ND |
0.5 / 0.5 (0.25‐0.5) ND |
0.5 / 0.5 (0.25‐0.5) R : 0% |
1 / 2 (1‐2) R : 0% |
1 / 2 (1 −2) R : 0% |
|
Candida krusei |
Period 1 |
64 ND |
0.25 R : 0% |
1 ND |
1 R :100% |
|||
Period 2 |
32 ND |
0.5 /0.5 (0.25‐0.5) R : 0% |
0.25 / 0.25 (0.25) ND |
0.5 / 1 (0.5 ‐ 1) ND |
0.25 / 0.5 (0.25 −0.5) R : 0% |
0.06 / 0.06 (0.03‐0.06) R : 0% |
0.12 / 0.12 (0.12) R : 0% |
MIC50/MIC90: Minimum inhibitory concentration encompassing 50% and 90% of isolates, respectively. R: resistant isolates according to the Clinical and Laboratory Standards Institute (CLSI) criteria. 15 ND: no defined criteria.